Baillie Gifford & Co. Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Baillie Gifford & Co. reduced its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 364,768 shares of the company’s stock after selling 40,657 shares during the quarter. Baillie Gifford & Co.’s holdings in CRISPR Therapeutics were worth $17,137,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of CRSP. Global Trust Asset Management LLC grew its stake in CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC grew its position in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics in the second quarter worth about $35,000. Finally, Denver PWM LLC purchased a new stake in shares of CRISPR Therapeutics in the second quarter worth about $45,000. Institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Down 7.5 %

Shares of CRISPR Therapeutics stock opened at $50.73 on Wednesday. The stock’s fifty day moving average is $47.70 and its two-hundred day moving average is $52.14. CRISPR Therapeutics AG has a 52 week low of $43.42 and a 52 week high of $91.10. The company has a market capitalization of $4.33 billion, a PE ratio of -17.93 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the prior year, the business posted ($1.41) earnings per share. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several research analyst reports. Truist Financial cut their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Barclays decreased their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus decreased their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $74.94.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.